ArticleFrontiers in neurology2025
Efficacy of
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Ginkgo Biloba for Alzheimer's Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment-What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?Brain sciences · 2026Review
- Ginkgetin: A Promising Multitarget Agent for Diverse Diseases.Biomolecules · 2026Review
- A Multi-Axis Framework for Late-Life Alzheimer's Disease Interpretation.Journal of personalized medicine · 2026Review
- GuiLingJi ameliorates mild cognitive impairment by targeting unsaturated fatty acid metabolism to inhibit GPR120/NF-κB mediated neuroinflammation.Frontiers in pharmacology · 2026Article
- Subcutaneous application ofFrontiers in public health · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mild cognitive impairment (MCI) with amyloid PET positivity represents a prodromal stage of Alzheimer's disease (AD), yet no disease-modifying therapies are currently approved. Objective: This study evaluated whether Methods: In this retrospective cohort study, 64 amyloid PET-positive MCI patients were followed for 12 months. Participants received either oral Results: At 12 months, the Ginkgo group showed significantly higher responder rates (100% vs. 59.1%, Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.